-
Tuesday, January 26, 2010 | 9:00 AM - 5:00 PM
Organizers: Lawrence P. Wennogle (Intra-Cellular Therapies, Inc.) and Peter Hutson (Merck and Co., Inc.)
The symposium will focus on phosphodiesterase (PDE) inhibitors for schizophrenia and cognitive disorders, review the theoretical basis of different PDEs, and chart the most recent progress towards human clinical testing.
Friday, January 29, 2010 | 1:00 PM - 5:00 PM
Organizers: Katalin Kauser (Boehringer Ingelheim Pharmaceuticals) and Christine Teutsch (Boehringer Ingelheim Pharmaceuticals)
The renin-angiotensin system is critical to blood pressure control. This symposium will highlight the importance of blocking the deleterious effects of Angiotensin II and describe a mechanistic basis for a more generalized cardiovascular protection.
Friday, April 23, 2010 | 7:45 AM - 6:00 PM
Organizers: Paul Coplan (Wyeth Pharmaceuticals), Baruch Fischhoff (Carnegie Mellon University), Theresa Mullin (FDA), and Alice Till (PhRMA)
This conference will focus on a formalized, systematic approach for assessing drug risks and benefits in the context of regulatory decisions about which drugs should come to market. Discussion will include ways to improve the transparency and communication of FDA decisions to the general public.
Tuesday, October 27, 2009 | 1:00 PM - 5:00 PM
Speakers: Suzanne M. de la Monte (Brown Medical School), William L. Klein (Northwestern University), José A. Luchsinger (Columbia University), Mark Mattson (National Institute on Aging, NIH)
Alzheimer’s disease (AD) has been called Type 3 diabetes, unique to the brain; others suggest that diabetes is a risk factor for AD. This symposium will discuss the significance of cerebral metabolic disturbances in Alzheimer's disease.
Wednesday, September 30, 2009 | 8:30 AM - 7:00 PM
Chair: J. William Langston (The Parkinson's Institute and Clinical Center)
Held in partnership with the Michael J. Fox Foundation, this meeting will highlight novel advances in basic and translational research that impact understanding of Parkinson's Disease and its treatment.
Tuesday, September 22, 2009 | 1:00 PM - 5:15 PM
Speakers: Joffre Baker (Genomic Health, Inc.), Ken Carter (Clinical Data, Inc.), Gary Kelloff (National Cancer Institute/NIH), Bruce Quinn (Foley Hoag LLP), Jorge M. Torres (Fish & Richardson P.C.)
As the medical field evolves to recognize the uniqueness of each individual’s disease, there is a growing certainty that particular drugs work better in subsets of patients we could not previously identify or segregate. This symposium will look at way the industry is looking to understand how to jointly develop new technological assays as diagnostics to be used with the new generation of targeted agents.
Wednesday, September 9, 2009 | 4:00 PM - 6:30 PM
Speakers: Akira Kawamura (CUNY-Hunter College), Tom Kodadek (The Scripps Research Institute), and John Koh (University of Delaware)
Small molecules can provide novel insights into biological processes. This meeting will focus on the role of these powerful molecular tools for immunology and cancer research.
|
-
eBriefing
Speakers: John Koh (University of Delaware), Akira Kawamura (Hunter College, City University of New York), and Tom Kodadek (The Scripps Research Institute)
From traditional Asian herbs to high-tech computational approaches, chemical biologists are using everything in their arsenal to identify promising new drug candidates.
eBriefing
Keynote Speaker: Adrian Whitty (Boston University)
In this new eBriefing, graduate students and postdocs from chemical biology labs around the New York area describe efforts to find and synthesize molecules that bind to proteins or DNA in useful ways.
eBriefing
Organizers: Anthony Atala (Wake Forest University), Stacie Bloom (New York Academy of Sciences), Yilin Cao (Shanghai Jiao Tong University), Anita Chong (The University of Chicago), Stefanie Dimmeler (University of Frankfurt), Michael P. Sheetz (Columbia University), Qiming Zhan (Chinese Academy of Medical Sciences), Alex Zhang (Sanofi Aventis), Chunhua Zhao (Chinese Academy of Medical Sciences)
A recent international conference in Beijing focused on exciting developments in fields like stem cell biology, tissue engineering, and xenotransplantation. A new eBriefing documents the event.
eBriefing
Speakers: Susan Taylor (University of California, San Diego), Vincent Stoll (Abbott Laboratories), Harren Jhoti (Astex Therapeutics), and Stephen Burley (SGX Pharmaceuticals)
Protein kinases play a key role in almost every major pathway in eukaryotic cells. A new eBriefing reports how structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.
eBriefing
Organizer: Albert Ko (Weill-Cornell Medical College)
As a new eBriefing explains, regions of Southeast Asia, Africa, and Latin America bear the greatest burden from meningococcal and pneumococcal diseases, dengue, and dengue hemorrhagic fever, in part because life-saving vaccines have not been broadly implemented.
Webinar Archive
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
Webinar Archive
May 28, 2009
Vaccine experts and public health officials met at the Academy on May 28, 2009 to discuss the latest about the outbreak.
Webinar Archive
May 20, 2009
Regions of Southeast Asia, Africa, and Latin America bear the greatest burden from infectious diseases, in part because life-saving vaccines have not been broadly implemented. How can they be delivered to those who need them most?
Webinar Archive
April 28, 2009
Protein kinases play a key role in almost every major pathway in eukaryotic cells. Structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.
|